Completed PHASE1 INTERVENTIONAL 3-arm NCT03164109

A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers

Sponsor: Galera Therapeutics, Inc.

Interventions GC4419 IV Oral moxifloxacin Placebo

Updated 7 times since 2017 Last updated: Nov 15, 2017 Started: Aug 18, 2017 Primary completion: Oct 13, 2017 Completion: Oct 13, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and Healthy Volunteers and is currently completed. Galera Therapeutics, Inc. leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
Jun 2017 — Dec 2017 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Galera Therapeutics, Inc.
Syneos Health

Data source: Galera Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia